and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.
Participating Organization(s) |
National Institutes of Health (NIH) |
National Cancer Institute (NCI) |
|
Funding Opportunity Title |
Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20) |
Activity Code |
P20 Exploratory Grants |
Announcement Type |
Reissue of PAR-13-068 |
Related Notices |
|
Funding Opportunity Announcement (FOA) Number |
PAR-14-152 |
Companion Funding Opportunity |
None |
Catalog of Federal Domestic Assistance (CFDA) Number(s) |
93.398 |
Funding Opportunity Purpose |
This Funding Opportunity Announcement (FOA) invites P20 planning grant applications for the implementation of collaborative partnership awards between Institutions serving communities with cancer health disparities and NCI-designated Cancer Centers (or Cancer Centers with highly integrated cancer research programs). For the purpose of this FOA, "the Institution(s)" will refer to academic or other organizations serving communities with cancer health disparities. This FOA is designed to facilitate the planning and execution of focused collaborations in cancer-related research, training/career development, and education. A major goal of the NCI P20 partnership awards is to provide support for investigators at the Institutions and Cancer Centers to conduct cancer pilot projects and training and education programs. The pilot projects and programs will allow awardees to obtain preliminary data and lead to competitive grant applications for funding by the NIH/NCI and/or other Federal/Non-Federal agencies. |
Posted Date |
March 10, 2014 |
Open Date (Earliest Submission Date) |
April 16, 2014 |
Letter of Intent Due Date(s) |
April 16, 2014; February 19, 2015 |
Application Due Date(s) |
May 16, 2014; March 19, 2015, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. |
AIDS Application Due Date(s) |
Not Applicable |
Scientific Merit Review |
July 2014; June/July 2015 |
Advisory Council Review |
October 2014; October 2015 |
Earliest Start Date |
October 2014; October 2015 |
Expiration Date |
March 20, 2015 |
Due Dates for E.O. 12372 |
Not Applicable |
NIH’s new Application Submission System & Interface for Submission Tracking (ASSIST) is available for the electronic preparation and submission of multi-project applications through Grants.gov to NIH. Applications to this FOA must be submitted electronically; paper applications will not be accepted. ASSIST replaces the Grants.gov downloadable forms currently used with most NIH opportunities and provides many features to enable electronic multi-project application submission and improve data quality, including: pre-population of organization and PD/PI data, pre-submission validation of many agency business rules and the generation of data summaries in the application image used for review.
Required Application Instructions
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts) and where instructions in the Application Guide are directly related to the Grants.gov downloadable forms currently used with most NIH opportunities. Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.
Part 1. Overview Information
Part 2. Full Text of the Announcement
Section I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission
Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information
This Funding Opportunity Announcement (FOA) invites P20 grant applications for the implementation of partnership awards between Institutions serving communities with cancer health disparities and NCI-designated Cancer Centers (or Cancer Centers with highly integrated cancer research programs). For the purpose of this FOA, "the Institutions" will refer to academic or other organizations serving communities with cancer health disparities. This FOA is designed to facilitate planning and implementation of focused collaborations in cancer-related research and training (career development) and education. A major goal of the NCI P20 partnership awards is to provide support for investigators at the Institutions and NCI-designated Cancer Centers to conduct cancer pilot projects and programs, which should allow awardees to obtain preliminary data that will lead to their submission of competitively funded grant applications to the NIH/NCI. In addition, educational programs designed to enhance outreach efforts at Cancer Centers may result in increased participation of underserved patients in cancer and/or cancer health disparities-related clinical trials. Notably, the P20 grant application must be submitted as a clearly documented partnership between the Institution and Cancer Center. For each partnership, two separate applications must be submitted: one from the Institution and one from the Cancer Center.
The NCI Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20) Program is part of the NCI Partnerships to Advance Cancer Health Equity (PACHE) Program (http://crchd.cancer.gov/research/pache-overview.html), designed to promote and build collaborative research, training , career development, and education efforts between the Institutions and the NCI-designated Cancer Centers (or Cancer Centers with highly integrated cancer research programs) as described below:
1) Collaborative pilot research project(s) in any area of cancer-related basic, clinical, translational, prevention, control, behavioral and/or population research; and
2) Collaborative cancer training (career development and education programs) designed to train students and scientists, as well as to augment existing or to create new curricula in the Institutions and/or enhance outreach efforts at Cancer Centers to increase participation of underserved populations in cancer and cancer health disparities-related clinical trials.
The objective of the pilot projects and programs funded by the P20 partnership awards is to gather preliminary data that will allow the submission of grant applications to the NIH/NCI to obtain funding through grant mechanisms such as:
The disparities in cancer incidence, morbidity, and mortality in underserved populations, including racial and ethnic populations and socio-economically, disadvantaged populations have continued to rise over several decades, despite the significant progress in other aspects of cancer research. For example, the incidence of colon and lung cancers in Alaska Native and African American men and women are higher than that of other ethnic groups. The 5-year cancer survival rates (e.g., for persons with lung, ovarian, prostate, colon, or breast cancers) in the Native American, African American, Hawaiian, and Hispanic American populations are lower than in the Japanese and White American populations. Increasing disparity is seen in patterns of prostate cancer among African American males compared with White males in the southeastern United States (U.S.), particularly in rural areas (http://statecancerprofiles.cancer.gov/). Clearly, more research is needed to better understand and overcome these and other cancer health disparities.
Institutions working to reduce health disparities among underserved populations support a pool of faculty and investigators who are culturally competent, and have unique expertise to conduct research on cancer health disparities. In addition, this pool of faculty and investigators have the expertise to establish high quality educational programs for persons interested in working with racial/ethnic and the underserved populations. However, investigators at these Institutions have to overcome barriers (e.g., limited infrastructure and resources) in developing and sustaining independent programs in cancer and/or cancer health disparities research.
The NCI-designated Cancer Centers are geographically dispersed, research-intensive institutions with well-organized programs for training cancer scientists. They are the major organized units supported by the NCI to: conduct cancer research; sponsor cancer-related research training in the basic, clinical, translational, and population sciences; provide informational services; and develop and sustain educational and/or outreach programs that benefit their communities. Yet, Cancer Centers can (and should) play a greater role in facilitating the following activities: 1) conducting research pertinent to cancer in underserved, isolated, and socio-economically disadvantaged groups; 2) training scientists in the care and treatment of individuals from populations with health disparities; 3) reaching out to and partnering with different underserved populations in their communities; and 4) bringing the benefits of advances in cancer research to their underserved communities and populations.
The NCI Partnerships to Advance Cancer Health Equity (PACHE) Program aims to build and sustain excellence. The P20 Program serves as a nurturing environment to allow for the development of new pilot projects and programs, and to obtain preliminary data that will lead to the submission of competitively funded NCI grant applications. As part of the PACHE Program, the P20 Partnership grant supports collaborative efforts in two broad target areas: Cancer Research and Cancer Training/Career development/Education.
The partnership applications must be centered on the following two target areas:
1) Cancer Research. A joint pilot research project may be in any area of cancer-related basic, clinical, translational, prevention, control, behavioral and/or population research. Partnership investigators are encouraged to develop research applications in translational research as defined by the NCI, emerging technologies such as nanotechnology, proteomics, genomics, and imaging, and research focusing on pediatric, adolescent, and young adult cancers. The NCI encourages the development of research projects leading to increased biospecimen collection from underserved populations, a critical endeavor to potentially elucidate the biological and genetic factors associated with cancer health disparities. Joint research projects conducted primarily at the Institutions serving underserved communities with cancer health disparities may be in any area of cancer research. Joint research projects conducted primarily at the Cancer Center must specifically address areas of cancer disparity in underserved populations.
2) Cancer training, career development and education. Training and Education programs are encouraged but not limited to the recruitiment of students and investigators from cancer health disparity populations (e.g., racial, ethnic, disabled, rural, medically underserved, etc.) and the recognition and understanding of the issues and problems associated with cancer disparities in underserved and socio-economically disadvantaged populations. Training (career development) programs relevant to cancer in translational research, behavioral research, emerging techniologies (nanotechnology, genomics, proteomics, and imaging) are a priority for NCI as there is a huge deficit of scientists from health disparity populations engaged in these research areas.
Education activities can focus on any effort to augment existing or create new curricula in the Institution and/or the Cancer Center. The development of curricula that focus on teaching students about emerging technologies (e.g., genomics, proteomics, and nanotechnology) and their use in cancer research are encouraged. A successful effort may result in the submission and obtaining an NCI education grant (R25) and should yield institutional commitments to integrate these curricula into their educational systems. In addition, educational programs designed to enhance outreach efforts at Cancer Centers to increase awareness in underserved communities about cancer risk, early detection, screening, prevention, and treatment may result in increased participation in cancer and cancer health disparities-related clinical trials.
The Program Directors/Principal Investigators (PD(s)/PI(s)), should include an evaluation plan of their partnership in preparation for NIH requests for information essential to an assessment of the effectiveness of this P20 program. Awardees may be contacted after the completion of this award for periodic updates on various aspects of high school, undergraduate, and graduate students' rates of graduation, entry into academic biomedical and behavioral science programs, publications, scientific presentations, etc. Periodic updates may also be requested of post-doctoral fellows and new/early stage investigators' employment histories, publications and presentations support from research grants or contracts, etc.
The overall evaluation of the program will be based on metrics that will include, but are not be limited to, the following:
Funding Instrument |
Grant: A support mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity. |
Application Types Allowed |
New The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types. |
Funds Available and Anticipated Number of Awards |
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. |
Award Budget |
Applications may request $275,000 in direct cost with partnered Institution or NCI-designated Cancer Center. The combined budget of direct costs cannot exceed $275,000 in the first year. This cap does not include third party (consortium) F&A costs if applicable |
Award Project Period |
Applicants may apply for up to 4 years of support. |
NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.
Higher Education Institutions
The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:
Nonprofits Other Than Institutions of Higher Education
For-Profit Organizations
Governments
Other
Each partnership must include both types of institutions: 1) an Institution serving communities with cancer health disparities; and 2) an NCI-designated Cancer Center (or Cancer Centers with highly integrated cancer research programs).
Non-domestic (non-U.S.) Entities (Foreign Institutions) are
not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible
to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Applicant Organizations
Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.
Program Directors/Principal Investigators (PD(s)/PI(s))
All PD(s)/PI(s) must have an eRA Commons account and should work with their organizational officials to either create a new account or to affiliate an existing account with the applicant organization’s eRA Commons account. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.
Any individual(s) with the skills, knowledge, and resources
necessary to carry out the proposed research as the Program Director(s)/Principal
Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to
develop an application for support. Individuals from underserved cancer health
disparity populations (e.g., racial, ethnic, lower socio-economic status, disabled,
rural, medically underserved, etc.), from underrepresented racial and ethnic
groups as well as individuals with disabilities are encouraged to apply for NIH
support.
For institutions/organizations proposing multiple PDs/PIs, visit the Multiple
Program Director/Principal Investigator Policy and submission details in the Senior/Key
Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.
For further information on multiple PD(s)/PI(s), please see http://grants.nih.gov/grants/multi_pi
This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.
NIH will not accept any application that is essentially the same as one already reviewed within the past thirty-seven months (as described in the NIH Grants Policy Statement), except for submission:
Number of concurrent applications/awards. The NCI PACHE Program includes the P20 grant mechanism and the U54 cooperative agreement mechanism (Comprehensive Partnerships to Advance Cancer Health Equity [CPACHE]; http://grants.nih.gov/grants/guide/pa-files/PAR-12-055.html). Each Institution and Cancer Center may not have more than one P20 award and one U54 award simultaneously within the same partnering Institutions. However, the partnering institutions can establish and apply for P20 partnerships with different partner institutions.
Applicants can access the SF424 (R&R) application package associated with this funding opportunity using the Apply for Grant Electronically button in this FOA or following the directions provided at Grants.gov.
Most applicants will use NIH’s ASSIST system to prepare and submit applications through Grants.gov to NIH. Applications prepared and submitted using applicant systems capable of submitting electronic multi-project applications to Grants.gov will also be accepted.
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed in this funding opportunity announcement to do otherwise and where instructions in the Application Guide are directly related to the Grants.gov downloadable forms currently used with most NIH opportunities. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
For information on Application Submission and Receipt, visit Frequently Asked Questions Application Guide, Electronic Submission of Grant Applications.
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.
By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:
The letter of intent should be sent to:
Carmen P. Moten, Ph.D., M.P.H.
Center to Reduce Cancer Health Disparities
National Cancer Institute
9609 Medical Center Drive, Room 6W242
Bethesda, MD 20892-9746 (for regular mail)
Rockville, MD 20850 (for express delivery)
Telephone: 240-276-6181
Email: cmoten@mail.nih.gov
Component Types Available in ASSIST |
Research Strategy/Program Plan Page Limits |
Overall |
12 |
Admin Core (use for Administrative Core) |
12 |
Project (use for Pilot Research Projects) |
12 |
Train Edu Prog (use for Training and Education Program) |
12 |
Additional page limits described in the SF424 Application Guide and the Table of Page Limits must be followed.
The following section supplements the instructions found in the SF424 (R&R) Application Guide, and should be used for preparing a multi-component application.
The application should consist of the following components:
Special Requirement: As stated in Section I of this FOA, each P20 application must be submitted as a clearly documented partnership between the Institution and Cancer Center. For each partnership, two separate applications must be submitted: one from the Institution and one from the Cancer Center.
When preparing your application in ASSIST, use Component Type Overall .
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.
SF424 (R&R) Cover (Overall)
Complete entire form.
Descriptive Title of Applicant's Project: To allow NIH to identify the set of two collaborative P20 applications, the titles for each application in the set must have the following format: a 1/2 or "2/2" indicator + identical title. Titles may not exceed 80 characters in length, including the tag (i.e., 1/2 or 2/2) at the beginning of the title.
Cover Letter: The Cover Letter is one pdf file only. Therefore, it must include the information requested below on the collaborative applications from the Institutions and Cancer Centers. The following collaborative information is required in the Cover Letter: a listing of BOTH applications that are a part of the set of collaborative P20 applications being submitted, including for each: 1) the PD/PI(s) name(s), 2) the Title (including the tag (i.e., 1/2 or "2/2"), and 3) the Applicant Institution. Each partnering institution should submit an identical listing.
PHS 398 Cover Page Supplement (Overall)
Note: Human Embryonic Stem Cell lines from other components should be repeated in cell line table in Overall component.
Research & Related Other Project Information (Overall)
Follow standard instructions.
Project/Performance Site Location(s) (Overall)
Enter primary site only.
A summary of Project/Performance Sites in the Overall section of the assembled application image in eRA Commons compiled from data collected in the other components will be generated upon submission.
Research & Related Senior/Key Person Profile (Overall)
Include only the Project Director/Principal Investigator (PD/PI) and any multi-PDs/PIs (if applicable to this FOA) for the entire application.
Contact PD/PI: Each application may have multiple PDs/PIs, but one PD/PI from each partnering Institution and Cancer Center is expected to be the designated contact PD/PI.
A summary of Senior/Key Persons followed by their Biographical Sketches in the Overall section of the assembled application image in eRA Commons will be generated upon submission.
Budget (Overall)
The only budget information included in the Overall component is the Estimated Project Funding section of the SF424 (R&R) Cover.
A budget summary in the Overall section of the assembled application image in eRA Commons compiled from detailed budget data collected in the other components will be generated upon submission.
PHS 398 Research Plan (Overall)
Introduction to Application: For Resubmission and Revision applications, an Introduction to the Application is required. The Introduction to the Application should be identical for both the Institution and Cancer Center applications.
Specific Aims: State the objectives of the collaboration. Outline the overall goals relevant to providing support for investigators at both the Institution and Cancer Center to conduct cancer pilot projects and training and education programs. Specific Aims must be identical for both collaborative applications.
Research Strategy: The Overall research strategy should be identical for both the Institution and the Cancer Center partnership applications. Although the overall objectives of the two applications must be the same, the actual activities proposed for the two applications should demonstrate how the Institution and the Cancer Center requests both differ and complement each other in achieving their common objectives.
The research strategy should clearly denote the nature of the interactions and deliberations that occurred between the Institution and the Cancer Center during the preparation of these applications (and identify the individuals involved).
The Research Strategy is limited to a brief descriptive summary of the following areas of the P20 that bring synergy to the Institution and Cancer Center partnerships:
The Pilot Research Project and Training and Education Program sections of this PAR require a more detailed description of project and program area listed above.
Letters of Support: Each application must include written "Letters-of-Commitment" from the respective leadership of both institutions to show support of the partnership and commitment to additional resources necessary to ensure that these partnerships will have the maximum sustainability. In addition, if Native Americans are involved, a Letter of Commitment from the Tribal Nation Leader is also required.
Complete and specific descriptions of these additional resources in the Letters of Support should include the following items:
When the PD/PI from the Institution or Cancer Center is an individual with no prior experience as a PD/PI on a peer reviewed grant, there must be a written "Letter-of-Support" from a senior member (e.g., Department Chair, Dean, Cancer Center Director) of the Institution or Cancer Center. In the letter, the senior member is expected to indicate his/her qualifications and the willingness to provide guidance to the inexperienced PD/PI.
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans (Data Sharing Plan, Sharing Model Organisms, and Genome Wide Association Studies (GWAS)) as provided in the SF424 (R&R) Application Guide, with the following modification:
Appendix: Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
When preparing your application in ASSIST, use Component Type Admin Core.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.
SF424 (R&R) Cover (Administrative Core)
Complete only the following fields:
PHS 398 Cover Page Supplement (Administrative Core)
Enter Human Embryonic Stem Cells in each relevant component.
Research & Related Other Project Information (Administrative Core)
Human Subjects: Answer only the Are Human Subjects Involved? and 'Is the Project Exempt from Federal regulations? questions.
Vertebrate Animals: Answer only the Are Vertebrate Animals Used? question.
Project Narrative: Do not complete.
Project /Performance Site Location(s) (Administrative Core)
List all performance sites that apply to the specific component.
Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.
Research & Related Senior/Key Person Profile (Administrative Core)
Budget (Administrative Core)
Administrative costs (which may be higher in the early stage of development and lower in the late stages) for managing the planning effort, such as salaries for key personnel, travel for key personnel (e.g., costs related to attendance at a biennial PACHE workshop), equipment, and supplies to support an administrative structure.
PHS 398 Research Plan (Administrative Core)
Introduction to Application: For Resubmission applications, an Introduction to Application is allowed for each component
Specific Aims: Identify the specific goals of the Administrative Core.
Research Strategy: Succinctly address the following items:
Leadership: Discuss the leadership qualifications, both scientific and administrative, and the time commitment of the PD(s)/PI(s) for the overall successful conduct of the PACHE Program. Detail the plans for the organizational, administrative, and scientific management (both basic and clinical research) of the PACHE Program. Describe and/or diagram the chain of authority for decision making and administration within the program. Leadership with respect to initiating, facilitating, and implementing successful translational/clinical research collaborations should be discussed in the Administrative Core section of the Overall component.
Administrative Management: Describe the plans for the fiscal management, clerical support, manuscript preparation and compliance to NIH public access policy (PMCID), and meeting organizations. Quality control and communication aspects of the grant, particularly if more than one institution is involved in the PACHE Program should be discussed. A succession plan should be included which describes the process by which new leadership will be selected in the event that the PACHE PD(s)/PI(s) is no longer willing or able to lead the PACHE. A statement of commitment to attend NCI sponsored meetings/workshops and NCI-related activities should also be included.
Internal Advisory Committee (IAC). The PD(s)/PI(s) from both partnering components may convene a common Internal Advisory Committee (IAC). The IAC must have equal numerical representation of members from the Institution and Cancer Center. A co-chair representing the Institution and a co-chair representing the Cancer Center must be selected among the key personnel. PD(s)/PI(s) may not hold the positions of co-chair. The IAC may include community stakeholders with relevant interest and expertise of the partnership objectives. Each new pilot project and training and education program should be evaluated for scientific merit, relevance to the partnership objectives, potential to generate publishable data for peer-reviewed journals, and potential to develop into a competitive grant application to be submitted to NIH/NCI or other equivalent funding agencies. When a pilot project or training and education program co-leader is an early stage investigator, the application of both the Institution and Cancer Center must be evaluated for the appropriateness of the Career Development and Mentorship Plan. In addition to reviewing and prioritizing new pilot projects/programs, the IAC will also evaluate ongoing pilot projects/programs and advise the PD(s)/PI(s) from both partnering components as to the general activities of the partnership and how they may contribute effectively to achieving high priority goals and objectives.
Specific additional items to provide in this section (under indicated headings):
(i) Estimated Timeline for Initial Planning, Priority-Setting, Implementation, and Evaluation Stages. This section should be identical for both the Institution and the Cancer Center applications. Based on prior experience, interactions, and progress in planning, the two applications must clearly describe a collaborative planning process that includes the Planning, Priority-Setting, Implementation, and Evaluation Stages. PD(s)/PI(s) should include a chronological narrative or table listing the specific first year, second year, third year, and fourth year objectives that are expected to be achieved. For each objective, a brief statement should be made about the separate contributions of the Institution and the Cancer Center in order to achieve success. The intent of these P20 partnership awards is to provide support for cancer pilot projects and programs for up to 4 years to perform feasibility studies and obtain preliminary data that will lead to the submission of competitively funded grant applications to NCI and/or other sources of peer-review.
(ii) Initial Planning Stage. This section should be identical for both the Institution and the Cancer Center applications. The applicants should clearly describe each planning activity proposed by the Institution and the Cancer Center to ensure a highly interactive and integrated effort between their faculty and scientists. The roles and activities of the Internal Advisory Committee (IAC) should be clearly described (see IAC above). The applicants should also relate each planning activity (e.g., workshop, retreat, executive meeting) to specific objectives and name the specific faculty and interests (e.g., training, clinical oncology researchers, research in prostate cancer, establishing new curriculum in cancer health disparities, nutrition) involved in each activity.
(iii) Priority-Setting Stage. This section should be identical for both the Institution and the Cancer Center applications. In the Priority-Setting Stage, the participants must select the areas of greatest promise for implementation targeting specific pilot projects or pilot programs based on merit and potential to result in a successful grant application (the PD(s)/PI(s) from both partnering components should describe the process used by the IAC to evaluate new and ongoing pilot projects/programs). Clearly describe how the specific pilot projects/programs will be prioritized and selected for implementation based on their merit and greatest potential for success.
(iv) Implementation Stage. This section should be identical for both the Institution and the Cancer Center applications. The applicants must provide brief descriptive summaries of the pilot cancer research project(s) and the joint cancer training and education program (relevant to cancer in translational research, behavioral research, and emerging technologies) to acquire preliminary data to submit a specific competitive grant application.
(v) Evaluation Stage. This section should be identical for both the Institution and the Cancer Center applications. The applications must describe an evaluation plan to assess for example various aspects of high school, undergraduate, and graduate students' rates of graduation, entry into academic biomedical and behavioral science programs, publications and presentations, post-doctoral fellows and new/early stage investigators' employment histories, publications support from research grants or contracts, etc. In addition, an evaluation plan to assess pilot programs in cancer training and education (including curriculum development and/or outreach activities).
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans (Data Sharing Plan, Sharing Model Organisms, and Genome Wide Association Studies (GWAS)) as provided in the SF424 (R&R) Application Guide.
Appendix: Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
Planned Enrollment Report (Administrative Core)
When conducting clinical research, follow all instructions for completing Planned Enrollment Reports as described in the SF424 (R&R) Application Guide.
PHS 398 Cumulative Inclusion Enrollment Report (Administrative Core)
When conducting clinical research, follow all instructions for completing Cumulative Inclusion Enrollment Report as described in the SF424 (R&R) Application Guide.
When preparing your application in ASSIST, use Component Type Project'.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.
The description of each pilot project/program should be provided in the following format:
SF424 (R&R) Cover (Pilot Research Project)
Complete only the following fields:
PHS 398 Cover Page Supplement (Pilot Research Project)Enter Human Embryonic Stem Cells in each relevant component.
Research & Related Other Project Information (Pilot Research Project)
Human Subjects: Answer only the Are Human Subjects Involved? and 'Is the Project Exempt from Federal regulations? questions.
Vertebrate Animals: Answer only the Are Vertebrate Animals Used? question.
Project Narrative: Provide a short description of the proposed research goals.
Other Attachments: A career development plan (CDP) is warranted for Early Stage Investigators (ESIs) or other less experienced investigators of Pilot Research Projects. The mentor(s) should provide a general description of the CDP for the ESI (coordinated with the ESI's research strategy). The CDP should include:
Project/Performance Site Location(s) (Pilot Research Project)
List all performance sites that apply to the specific component.
Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.
Research & Related Senior/Key Person Profile (Pilot Research Project)
Budget
Individual research projects should have a detailed budget for the entire proposed project period.
Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.
PHS 398 Research Plan (Pilot Research Project)
Introduction to Application: For Resubmission applications, an Introduction to Application is allowed.
Specific Aims: State the hypothesis of the proposed pilot research project and its specific aims.
Research Strategy: For the purpose of this FOA, a Pilot Project supports research in any area of cancer-related basic, clinical, translational, prevention, control, behavioral, population, and/or outreach research. Partnership investigators are encouraged to develop pilot research projects in translational research as defined by the NCI, emerging technologies, such as nanotechnology, proteomics, genomics, and imaging, and research focusing on pediatric, adolescent, and young adult cancers. The NCI encourages the development of research projects leading to increased biospecimen collection from underserved populations, a critical endeavor to potentially elucidate the biological and genetic factors associated with cancer health disparities.
Joint pilot research projects conducted primarily at the Institutions serving underserved communities with cancer health disparities may be in any area of cancer-related basic, clinical, translational, prevention, control, behavioral and/or population research. These projects may focus, for example, on general areas of environmental carcinogenesis, cancer biology, molecular epidemiology, and/or behavioral issues related to cancer prevention, treatment, and control. Joint pilot research projects conducted primarily at the Cancer Center must specifically address areas of cancer disparity in underserved populations. All these efforts must be aimed at grant application submissions (e.g., R01 awards, projects on P01 or P50 awards or their equivalents).
Describe how this pilot research project relates to the overall priorities of the partnership and the target area(s). Include any preliminary data (if available).
Describe, as appropriate for the nature of the pilot research project, experimental methods/study design. For example, for a pilot project include the identification of the target pool (students, post-doctoral fellows, ESIs or other less experienced investigators) and the method of the project evaluation plan and tracking procedures.
Describe the roles played by the Institution and Cancer Center co-investigators/mentors. Identify which aspects of the pilot project will be conducted primarily at the Institution and which will be conducted at the Cancer Center. Pilot projects conducted at the Institution may be in any area of cancer research, but pilot projects conducted at the Cancer Center must specifically address cancer health disparities research.
Letters of Support: Letters indicating institutional commitment and any letter of support for the proposed research project should be included.
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans (Data Sharing Plan, Sharing Model Organisms, and Genome Wide Association Studies (GWAS)) as provided in the SF424 (R&R) Application Guide.
Appendix: Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
Planned Enrollment Report
When conducting clinical research, follow all instructions for completing Planned Enrollment Reports as described in the SF424 (R&R) Application Guide.
PHS 398 Cumulative Inclusion Enrollment Report
When conducting clinical research, follow all instructions for completing Cumulative Inclusion Enrollment Report as described in the SF424 (R&R) Application Guide.
When preparing your application in ASSIST, use Component Type Train Edu Prog'.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.
SF424 (R&R) Cover (Training and Education Program)
Complete only the following fields:
PHS 398 Cover Page Supplement (Training and Education Program)
Enter Human Embryonic Stem Cells in each relevant component.
Research & Related Other Project Information (Training and Education Program)
Human Subjects: Answer only the Are Human Subjects Involved? and 'Is the Project Exempt from Federal regulations? questions.
Vertebrate Animals: Answer only the Are Vertebrate Animals Used? question.
Project Narrative: Provide a short description of the proposed research goals.
Other Attachments: A Career Development Plan (CDP) is warranted for Early Stage Investigators (ESIs) or other less experienced investigators of pilot training and education programs. The mentor(s) should provide a general description of the CDP for the ESI (coordinated with the ESI's training and education strategy). The CDP should include:
Project/Performance Site Location(s) (Training and Education Program)
List all performance sites that apply to the specific component.
Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.
Research & Related Senior/Key Person Profile (Training and Education Program)
Budget (Training and Education Program)
Prepare a detailed budget and justification for the Entire Proposed Period of Support.
Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.
PHS 398 Research Plan (Training and Education Program)
Introduction to Application: For Resubmission applications, an Introduction to Application is allowed.
Specific Aims: State the hypothesis of the proposed Training and Education Program and its specific aims.
Research Strategy: A Training and Education Program (TEP) must represent true collaborations that function seamlessly across the Institution and the Cancer Center. For example, training and education programs might provide graduate students at the Institutions opportunities to fulfill their research requirements in Cancer Center laboratories using state-of-the-art equipment and mentoring by Cancer Center investigators. On the other hand, Master degree programs at an Institution might be linked formally to doctoral training and education programs at Cancer Centers. Clinical research training programs at Institutions might also include rotations for medical students and residents working in Cancer Center laboratories. Other training and education programs may focus on minority cultural issues for all trainees, and clinical training and education programs at the Cancer Center might offer the use of current methodologies for national and international electronic communication on diagnosis and treatment of cancer for trainees. Successful activities in this area may lead to submissions of training grant applications (e.g., T32, K12,) as well as individual predoctoral fellowships (F31), individual postdoctoral fellowships (F32 and F33), career development awards (K01, K08, K23, K22), and research supplements (Diversity) for trainees. Applicants may consider for the training program activities proper tracking of trainees and an evaluation plan of the program.
The partnership applications are to focus on specific project goals relevant to building research capacity at the Institutions. The research strategy must describe, as appropriate, the nature of the training and education program, experimental methods/study design, or the training and education plans and objectives. For example, for a training program include the identification of the target pool (students, post-doctoral fellows, Early Stage Investigators (ESIs) or other less experienced investigators) and the method of the program evaluation plan and tracking procedures. Describe the role played by the Institution and Cancer Center Co-investigators/mentors. Identify which aspects of the Training and Education program will be conducted primarily at the Institution and which will be conducted at the Cancer Center. Training and Education Programs conducted primarily at the Institution may be in any area of cancer research, but Training and Education Programs conducted primarily at the Cancer Center must specifically address cancer health disparities research.
Educational Activities of TEP can focus on any effort to augment existing or create new curricula in the Institution and/or the Cancer Center that would apprise students and trainees in research, medicine, and public health of the need to reduce the disproportionate cancer burden in underserved populations and to motivate this population of students and trainees to pursue cancer research careers. The development of curricula that focus on teaching students about emerging technologies (e.g., genomics, proteomics, and nanotechnology) and their use in cancer research are encouraged. A successful effort may result in the submission of a competitive NCI education grant application (R25) and should yield institutional commitments to integrate these curricula into their educational systems. In addition, educational activities may enhance outreach efforts at Cancer Centers to assist underserved communities developing, implementing, and sustaining culturally sensitive programs to increase awareness about cancer risk, early detection, screening, prevention, and treatment. Institutions and Cancer Centers may also combine their expertise by working with minority leaders and organizations in the community to develop Educational Outreach activities to encourage physicians and underserved communities to increase the recruitment and retention of health disparity populations (e.g., racial, ethnic, disabled, rural, medically underserved, etc.) into clinical trials and prevention protocols (weight reduction, tobacco cessation). Educational outreach activities must be hypothesis-driven and include appropriate research questions, tracking, and an evaluation plan.
The Training and Education Program should address the following:
Letters of Support: Letters indicating institutional commitment and any letter of support for the proposed training and education program should be included.
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans (Data Sharing Plan, Sharing Model Organisms, and Genome Wide Association Studies (GWAS)) as provided in the SF424 (R&R) Application Guide.
Appendix: Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
Planned Enrollment Report (Training and Education Program)
When conducting clinical research, follow all instructions for completing Planned Enrollment Reports as described in the SF424 (R&R) Application Guide.
PHS 398 Cumulative Inclusion Enrollment Report (Training and Education Program)
When conducting clinical research, follow all instructions for completing Cumulative Inclusion Enrollment Report as described in the SF424 (R&R) Application Guide.
Part I. Overview Information contains information about Key Dates. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission.
Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies) using ASSIST or other electronic submission systems. Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration.
Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.
Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.
This initiative is not subject to intergovernmental review.
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-award costs are allowable only as described in the NIH Grants Policy Statement.
Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.
For information on how your application will be automatically assembled for review and funding consideration after submission go to: http://grants.nih.gov/grants/ElectronicReceipt/files/Electronic_Multi-project_Application_Image_Assembly.pdf.
Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.
For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically.
Important
reminders:
All PD(s)/PI(s) and component Project Leads must include their
eRA Commons ID in the Credential field of the Senior/Key Person Profile
Component of the SF424(R&R) Application Package. Failure to register
in the Commons and to include a valid PD/PI Commons ID in the credential field
will prevent the successful submission of an electronic application to NIH.
The applicant organization must ensure that the DUNS number it provides on the
application is the same number used in the organization’s profile in the eRA
Commons and for the System for Award Management (SAM). Additional information
may be found in the SF424 (R&R) Application Guide.
See more
tips for avoiding common errors.
Upon receipt, applications will be evaluated for completeness by the Center for Scientific Review, NIH. Applications that are incomplete will not be reviewed.
Applicants are required to follow the instructions for post-submission materials, as described in NOT-OD-13-030.
Only the review criteria described below will be considered in the review process. As part of the NIH mission, all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.
Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project/program to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project/program proposed).
Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.
Significance
Does the project/program address an important problem or a critical barrier to progress in the field? If the aims of the project/program are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field? In addition, specific to this FOA: Does the proposed partnership or project/program address an important cancer or cancer health disparities problem? Will the proposed partnership or project/program have a significant effect on the broader field of health disparities?
Investigator(s)
Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project/program? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project? In addition, specific to this FOA: Does (Do) the investigator(s) have prior adequate training and experience in designing and implementing new training and education programs that are culturally appropriate interventions? Do the applicant(s) and other team members have prior experience in recruiting and training new and early stage investigators or other less experienced investigators?
Innovation
Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed? In addition, specific to this FOA: Does the application use a creative study design? Is the study design being proposed already in existence but being applied to new underserved populations? Will the proposed design be culturally tailored for the population of interest? Will plans be made available and flexible enough for modification, if found to be beneficial?
Approach
Are the overall strategy, methodology, and analyses
well-reasoned and appropriate to accomplish the specific aims of the project/program?
Are potential problems, alternative strategies, and benchmarks for success presented?
If the project is in the early stages of development, will the strategy
establish feasibility and will particularly risky aspects be managed?
If the project/program involves human subjects and/or NIH-defined clinical
research, are the plans to address 1) the protection of human subjects from
research risks, and 2) inclusion (or exclusion) of individuals on the basis of
sex/gender, race, and ethnicity, as well as the inclusion or exclusion of
children, justified in terms of the scientific goals and research strategy
proposed? In addition,
specific to this FOA: Are the methods for the Initial Planning
Stage that are proposed by the Institution and the Cancer Center to explore
areas of research and training opportunities adequate to ensure highly
interactive and integrated efforts between individual scientists and/or between
faculty and scientists? Is the duration of the initial planning stage needed to
identify areas of potential collaboration adequate?
Environment
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements? In addition, specific to this FOA: What is the strength of the evidence that the researchers and faculty of the Institution and the Cancer Center worked closely together in the preparation of the application? To what degree do the letters-of-support from senior faculty and/or Institutional/Center leaders address the need for mentoring of inexperienced PDs/PIs or for specific Institutional/Center commitments to ensure the success of the collaboration?
As applicable for the project/program proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.
Protections for Human Subjects
For research that involves human subjects but does
not involve one of the six categories of research that are exempt under 45 CFR
Part 46, the committee will evaluate the justification for involvement of human
subjects and the proposed protections from research risk relating to their
participation according to the following five review criteria: 1) risk to
subjects, 2) adequacy of protection against risks, 3) potential benefits to the
subjects and others, 4) importance of the knowledge to be gained, and 5) data
and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or
more of the six categories of research that are exempt under 45 CFR Part 46,
the committee will evaluate: 1) the justification for the exemption, 2) human
subjects involvement and characteristics, and 3) sources of materials. For
additional information on review of the Human Subjects section, please refer to
the Guidelines
for the Review of Human Subjects.
Inclusion of Women, Minorities, and Children
When the proposed project/program involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of children to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.
Vertebrate Animals
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
Biohazards
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
Resubmissions
For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.
Renewals
Not Applicable
Revisions
For Revisions, the committee will consider the appropriateness of the proposed expansion of the scope of the project. If the Revision application relates to a specific line of investigation presented in the original application that was not recommended for approval by the committee, then the committee will consider whether the responses to comments from the previous scientific review group are adequate and whether substantial changes are clearly evident.
As applicable for the project/program proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.
Applications from Foreign Organizations
Not Applicable
Select Agent Research
Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Resource Sharing Plans
Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: 1) Data Sharing Plan; 2) Sharing Model Organisms; and 3) Genome Wide Association Studies (GWAS).
Budget and Period of Support
Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by the NCI, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.
As part of the scientific peer review, all applications:
Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this FOA. Following initial peer review, recommended applications will receive a second level of review by the National Cancer Advisory Board. The following will be considered in making funding decisions:
After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons.
Information regarding the disposition of applications is available in the NIH Grants Policy Statement.
If the application is under consideration for funding, NIH
will request "just-in-time" information from the applicant as
described in the NIH Grants
Policy Statement.
A formal notification in the form of a Notice of Award (NoA) will be provided
to the applicant organization for successful applications. The NoA signed by
the grants management officer is the authorizing document and will be sent via
email to the grantee’s business official.
Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection
of an application for award is not an authorization to begin performance. Any
costs incurred before receipt of the NoA are at the recipient's risk. These
costs may be reimbursed only to the extent considered allowable pre-award costs.
Any application awarded in response to this FOA will be subject to the DUNS, SAM
Registration, and Transparency Act requirements as noted on the Award
Conditions and Information for NIH Grants website.
Awardee-selected projects that involve clinical trials or studies involving greater than minimal risk to human subjects require prior approval by NIH prior to initiation.
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.
Cooperative Agreement Terms and Conditions of Award
Not Applicable
When multiple years are involved, awardees will be required to submit the Non-Competing Continuation Grant Progress Report (PHS 2590 or RPPR) annually and financial statements as required in the NIH Grants Policy Statement.
A final progress report, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement.
The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.
We encourage inquiries concerning this funding opportunity
and welcome the opportunity to answer questions from potential applicants.
eRA Commons Help Desk (Questions regarding eRA Commons registration, submitting and tracking an application, documenting system problems that threaten submission by the due date, post submission issues)Telephone: 301-402-7469 or 866-504-9552 (Toll Free)
Web ticketing system: https://public.era.nih.gov/commonshelp
TTY: 301-451-5939
Email: commons@od.nih.gov
Grants.gov Customer Support (Questions
regarding Grants.gov registration and submission, downloading forms and
application packages)
Contact Center Telephone: 800-518-4726
Web ticketing system: https://grants-portal.psc.gov/ContactUs.aspx
Email: support@grants.gov
GrantsInfo (Questions regarding application instructions and
process, finding NIH grant resources)
Telephone: 301-710-0267
TTY: 301-451-5936
Email: GrantsInfo@nih.gov
Carmen P. Moten, Ph.D., M.P.H.
National Cancer Institute (NCI)
Telephone: 240-276-6181
Email: cmoten@mail.nih.gov
Referral Officer
National Cancer Institute (NCI)
Telephone: 240-276-6390
Email: ncirefof@dea.nci.nih.gov
Carol Perry
National Cancer Institute (NCI)
Telephone: 240-276-6282
Email: perryc@mail.nih.gov
Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Parts 74 and 92.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
| ||||||
|
|
|
Department of Health and Human Services (HHS) |
|
|||
|
NIH... Turning Discovery Into Health® Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |
||||||